SAMHD1 protects cancer cells from various nucleoside-based antimetabolites

References

• Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, Yatim A, Emiliani S, Schwartz O, Benkirane M. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011; 474:654-7; PMID:21613998; https://doi.org/10.1038/nature10117
   PubMed Web of Science ®Google Scholar
• Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011; 474:658-61; PMID:21720370; https://doi.org/10.1038/nature10195
   PubMed Web of Science ®Google Scholar
• Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, Bloch N, Maudet C, Bertrand M, Gramberg T, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 2013; 14:877; https://doi.org/10.1038/ni0813-877a
   Web of Science ®Google Scholar
• Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, Christodoulou E, Walker PA, Kelly G, Haire LF, Yap MW, et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 2011; 480:379-82; PMID:22056990; https://doi.org/10.1038/nature10623
   PubMed Web of Science ®Google Scholar
• Franzolin E, Pontarin G, Rampazzo C, Miazzi C, Ferraro P, Palumbo E, Reichard P, Bianchi V. The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator of DNA precursor pools in mammalian cells. Proc Natl Acad Sci U S A 2013; 110:14272-7; PMID:23858451; https://doi.org/10.1073/pnas.1312033110
   PubMed Web of Science ®Google Scholar
• Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, Carr IM, Fuller JC, Jackson RM, Lamb T, Briggs TA, et al. Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet 2009; 41:829-32; PMID:19525956; https://doi.org/10.1038/ng.373
   PubMed Web of Science ®Google Scholar
• Clifford R, Louis T, Robbe P, Ackroyd S, Burns A, Timbs AT, Wright Colopy G, Dreau H, Sigaux F, Judde JG, et al. SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood 2014; 123:1021-31; PMID:24335234; https://doi.org/10.1182/blood-2013-04-490847
   PubMed Web of Science ®Google Scholar
• Wang JL, Lu FZ, Shen XY, Wu Y, Zhao LT. SAMHD1 is down regulated in lung cancer by methylation and inhibits tumor cell proliferation. Biochem Biophys Res Commun 2014; 455:229-33; PMID:25449277; https://doi.org/10.1016/j.bbrc.2014.10.153
   PubMed Web of Science ®Google Scholar
• Rentoft M, Lindell K, Tran P, Chabes AL, Buckland RJ, Watt DL, Marjavaara L, Nilsson AK, Melin B, Trygg J, et al. Heterozygous colon cancer-associated mutations of SAMHD1 have functional significance. Proc Natl Acad Sci U S A 2016; 113:4723-8; PMID:27071091; https://doi.org/10.1073/pnas.1519128113
   PubMed Web of Science ®Google Scholar
• Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, et al. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat Med 2017; 23(2):250-255
   PubMed Web of Science ®Google Scholar
• Herold N, Rudd SG, Ljungblad L, Sanjiv K, Myrberg IH, Paulin CB, Heshmati Y, Hagenkort A, Kutzner J, Page BD, et al. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. Nat Med 2017; 23:256-63; PMID:28067901; https://doi.org/10.1038/nm.4265
   PubMed Web of Science ®Google Scholar
• Hollenbaugh JA, Shelton J, Tao S, Amiralaei S, Liu P, Lu X, Goetze RW, Zhou L, Nettles JH, Schinazi RF, et al. Substrates and Inhibitors of SAMHD1. PLoS One 2017; 12:e0169052; PMID:28046007; https://doi.org/10.1371/journal.pone.0169052
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:E359-86; PMID:25220842; https://doi.org/10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Taga T, Tomizawa D, Takahashi H, Adachi S. Acute myeloid leukemia in children: Current status and future directions. Pediatr Int 2016; 58:71-80; PMID:26645706; https://doi.org/10.1111/ped.12865
   PubMed Web of Science ®Google Scholar
• Ossenkoppele G, Lowenberg B. How I treat the older patient with acute myeloid leukemia. Blood 2015; 125:767-74; PMID:25515963; https://doi.org/10.1182/blood-2014-08-551499
   PubMed Web of Science ®Google Scholar
• Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J, Sawitsky A, Rosner F, Gussoff B, Silver RT, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968; 32:507-23; PMID:4879053
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E, 3rd. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331:896-903; PMID:8078551; https://doi.org/10.1056/NEJM199410063311402
   PubMed Web of Science ®Google Scholar
• Zittoun R, Marie JP, Delanian S, Suberville AM, Thevenin D. Prognostic value of in vitro uptake and retention of cytosine arabinoside in acute myelogenous leukemia. Semin Oncol 1987; 14:269-75; PMID:3473680
   PubMed Web of Science ®Google Scholar
• Early AP, Preisler HD, Slocum H, Rustum YM. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: Clinical response and pharmacology. Cancer Res 1982; 42:1587-94; PMID:6949642
   PubMed Web of Science ®Google Scholar
• Estey E, Plunkett W, Dixon D, Keating M, McCredie K, Freireich EJ. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1987; 1:580-3; PMID:3669771
   PubMed Web of Science ®Google Scholar
• Heinemann V, Jehn U. Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside. Leukemia 1990; 4:790-6; PMID:2232893
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Schleyer E, Unterhalt M, Kern W, Buchner T. Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells. Ther Drug Monit 1996; 18:341-9; PMID:8857548; https://doi.org/10.1097/00007691-199608000-00005
   PubMed Web of Science ®Google Scholar
• Kessel D, Hall TC, Rosenthal D. Uptake and phosphorylation of cytosine arabinoside by normal and leukemic human blood cells in vitro. Cancer Res 1969; 29:459-63; PMID:5250069
   PubMed Web of Science ®Google Scholar
• Rustum YM, Riva C, Preisler HD. Pharmacokinetic parameters of 1-beta-D-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C. Semin Oncol 1987; 14:141-8; PMID:3589689
   PubMed Web of Science ®Google Scholar
• Smyth JF, Robins AB, Leese CL. The metabolism of cytosine arabinoside as a predictive test for clinical response to the drug in acute myeloid leukaemia. Eur J Cancer 1976; 12:567-73; PMID:1066282; https://doi.org/10.1016/0014-2964(76)90164-X
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kawai Y, Goto N, Kishi S, Imamura S, Yoshida A, Urasaki Y, Fukushima T, Iwasaki H, Tsutani H, et al. Close correlation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia. Jpn J Cancer Res 2001; 92:975-82; PMID:11572766; https://doi.org/10.1111/j.1349-7006.2001.tb01188.x
   PubMedGoogle Scholar
• Cribier A, Descours B, Valadao AL, Laguette N, Benkirane M. Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1. Cell Rep 2013; 3:1036-43; PMID:23602554; https://doi.org/10.1016/j.celrep.2013.03.017
   PubMed Web of Science ®Google Scholar
• Welbourn S, Dutta SM, Semmes OJ, Strebel K. Restriction of virus infection but not catalytic dNTPase activity is regulated by phosphorylation of SAMHD1. J Virol 2013; 87:11516-24; PMID:23966382; https://doi.org/10.1128/JVI.01642-13
   PubMed Web of Science ®Google Scholar
• Arnold LH, Groom HC, Kunzelmann S, Schwefel D, Caswell SJ, Ordonez P, Mann MC, Rueschenbaum S, Goldstone DC, Pennell S, et al. Phospho-dependent regulation of SAMHD1 oligomerisation couples catalysis and restriction. PLoS Pathog 2015; 11:e1005194; PMID:26431200; https://doi.org/10.1371/journal.ppat.1005194
   PubMed Web of Science ®Google Scholar
• Kufe D, Spriggs D, Egan EM, Munroe D. Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. Blood 1984; 64:54-8; PMID:6587917
   PubMed Web of Science ®Google Scholar
• Major PP, Egan EM, Herrick DJ, Kufe DW. Effect of ARA-C incorporation on deoxyribonucleic acid synthesis in cells. Biochem Pharmacol 1982; 31:2937-40; PMID:7138584; https://doi.org/10.1016/0006-2952(82)90266-0
   PubMed Web of Science ®Google Scholar
• Plunkett W, Begleiter A, Liliemark JO, Reed JC. Why do drugs work in CLL? Leuk Lymphoma 1996; 22 Suppl 2:1-11; PMID:9021705; https://doi.org/10.3109/10428199609102699
   PubMed Web of Science ®Google Scholar
• Robak P, Robak T. Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treat Rev 2013; 39:851-61; PMID:23566572; https://doi.org/10.1016/j.ctrv.2013.03.006
   PubMed Web of Science ®Google Scholar
• Kaltoft K, Bisballe S, Rasmussen HF, Thestrup-Pedersen K, Thomsen K, Sterry W. A continuous T-cell line from a patient with Sezary syndrome. Arch Dermatol Res 1987; 279:293-8; PMID:3498444; https://doi.org/10.1007/BF00431220
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361:1249-59; PMID:19776406; https://doi.org/10.1056/NEJMoa0904544
   PubMed Web of Science ®Google Scholar
• Matos PM, Marin M, Ahn B, Lam W, Santos NC, Melikyan GB. Anionic lipids are required for vesicular stomatitis virus G protein-mediated single particle fusion with supported lipid bilayers. J Biol Chem 2013; 288:12416-25; PMID:23493401; https://doi.org/10.1074/jbc.M113.462028
   PubMed Web of Science ®Google Scholar
• Goujon C, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, Cimarelli A. With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIV(MAC). Gene Ther 2006; 13:991-4; PMID:16525481; https://doi.org/10.1038/sj.gt.3302753
   PubMed Web of Science ®Google Scholar
• Berger G, Goujon C, Darlix JL, Cimarelli A. SIVMAC Vpx improves the transduction of dendritic cells with nonintegrative HIV-1-derived vectors. Gene Ther 2009; 16:159-63; PMID:18668143; https://doi.org/10.1038/gt.2008.128
   PubMed Web of Science ®Google Scholar
• Berger G, Durand S, Goujon C, Nguyen XN, Cordeil S, Darlix JL, Cimarelli A. A simple, versatile and efficient method to genetically modify human monocyte-derived dendritic cells with HIV-1-derived lentiviral vectors. Nat Protoc 2011; 6:806-16; PMID:21637200; https://doi.org/10.1038/nprot.2011.327
   PubMed Web of Science ®Google Scholar
• Durand S, Nguyen XN, Turpin J, Cordeil S, Nazaret N, Croze S, Mahieux R, Lachuer J, Legras-Lachuer C, Cimarelli A. Tailored HIV-1 vectors for genetic modification of primary human dendritic cells and monocytes. J Virol 2013; 87:234-42; PMID:23077304; https://doi.org/10.1128/JVI.01459-12
   PubMed Web of Science ®Google Scholar
• Booth C, Gaspar HB, Thrasher AJ. Treating immunodeficiency through HSC gene therapy. Trends Mol Med 2016; 22:317-27; PMID:26993219; https://doi.org/10.1016/j.molmed.2016.02.002
   PubMed Web of Science ®Google Scholar
• Mansilla-Soto J, Riviere I, Boulad F, Sadelain M. Cell and gene therapy for the beta-thalassemias: Advances and prospects. Hum Gene Ther 2016; 27:295-304; PMID:27021486; https://doi.org/10.1089/hum.2016.037
   PubMed Web of Science ®Google Scholar
• Alton EW, Beekman JM, Boyd AC, Brand J, Carlon MS, Connolly MM, Chan M, Conlon S, Davidson HE, Davies JC, et al. Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. Thorax 2017; 72:137-47; PMID:27852956; https://doi.org/10.1136/thoraxjnl-2016-208406
   PubMed Web of Science ®Google Scholar
• Frecha C, Costa C, Negre D, Amirache F, Trono D, Rio P, Bueren J, Cosset FL, Verhoeyen E. A novel lentiviral vector targets gene transfer into human hematopoietic stem cells in marrow from patients with bone marrow failure syndrome and in vivo in humanized mice. Blood 2012; 119:1139-50; PMID:22117040; https://doi.org/10.1182/blood-2011-04-346619
   PubMed Web of Science ®Google Scholar
• Frecha C, Fusil F, Cosset FL, Verhoeyen E. In vivo gene delivery into hCD34+ cells in a humanized mouse model. Methods Mol Biol 2011; 737:367-90; PMID:21590405
   PubMedGoogle Scholar
• Sahin U, Kariko K, Tureci O. mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov 2014; 13:759-80; PMID:25233993; https://doi.org/10.1038/nrd4278
   PubMed Web of Science ®Google Scholar
• Kienle E, Senis E, Borner K, Niopek D, Wiedtke E, Grosse S, Grimm D. Engineering and evolution of synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuffling. J Vis Exp 2012; 3819; PMID:22491297; https://doi.org/10.3791/3819
   PubMed Web of Science ®Google Scholar
• Chen JJ, Jin MX, Zhu SL, Li F, Xing Y. The Synthesis and characteristic study of transferrin-conjugated liposomes carrying brain-derived neurotrophic factor. Biomed Mater Eng 2014; 24:2089-99; PMID:25226906
   PubMed Web of Science ®Google Scholar
• Morrell NT, Leucht P, Zhao L, Kim JB, ten Berge D, Ponnusamy K, Carre AL, Dudek H, Zachlederova M, McElhaney M, et al. Liposomal packaging generates Wnt protein with in vivo biological activity. PLoS One 2008; 3:e2930; PMID:18698373; https://doi.org/10.1371/journal.pone.0002930
   PubMed Web of Science ®Google Scholar
• Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, Hirsch BA, Kahwash SB, Heerema-McKenney A, Winter L, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol 2014; 32:3021-32; PMID:25092781; https://doi.org/10.1200/JCO.2014.55.3628
   PubMed Web of Science ®Google Scholar
• Merati M, Buethe DJ, Cooper KD, Honda KS, Wang H, Gerstenblith MR. Aggressive CD8(+) epidermotropic cutaneous T-cell lymphoma associated with homozygous mutation in SAMHD1. JAAD Case Rep 2015; 1:227-9; PMID:27051737; https://doi.org/10.1016/j.jdcr.2015.05.003
   PubMedGoogle Scholar
• Kodigepalli KM, Li M, Liu SL, Wu L. Exogenous expression of SAMHD1 inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma-derived HuT78 cells. Cell Cycle 2017; 16:179-88; PMID:27929746; https://doi.org/10.1080/15384101.2016.1261226
   PubMed Web of Science ®Google Scholar
• Bonifati S, Daly MB, St Gelais C, Kim SH, Hollenbaugh JA, Shepard C, Kennedy EM, Kim DH, Schinazi RF, Kim B, et al. SAMHD1 controls cell cycle status, apoptosis and HIV-1 infection in monocytic THP-1 cells. Virology 2016; 495:92-100; PMID:27183329; https://doi.org/10.1016/j.virol.2016.05.002
   PubMed Web of Science ®Google Scholar
• Frecha C, Szecsi J, Cosset FL, Verhoeyen E. Strategies for targeting lentiviral vectors. Curr Gene Ther 2008; 8:449-60; PMID:19075628; https://doi.org/10.2174/156652308786848003
   PubMed Web of Science ®Google Scholar
• Arnold LH, Kunzelmann S, Webb MR, Taylor IA. A continuous enzyme-coupled assay for triphosphohydrolase activity of HIV-1 restriction factor SAMHD1. Antimicrob Agents Chemother 2015; 59:186-92; PMID:25331707; https://doi.org/10.1128/AAC.03903-14
   PubMed Web of Science ®Google Scholar
• Seamon KJ, Stivers JT. A high-throughput enzyme-coupled assay for SAMHD1 dNTPase. J Biomol Screen 2015; 20:801-9; PMID:25755265; https://doi.org/10.1177/1087057115575150
   PubMedGoogle Scholar
• Seamon KJ, Hansen EC, Kadina AP, Kashemirov BA, McKenna CE, Bumpus NN, Stivers JT. Small molecule inhibition of SAMHD1 dNTPase by tetramer destabilization. J Am Chem Soc 2014; 136:9822-5; PMID:24983818; https://doi.org/10.1021/ja5035717
   PubMed Web of Science ®Google Scholar
• Ladner RD. The role of dUTPase and uracil-DNA repair in cancer chemotherapy. Curr Protein Pept Sci 2001; 2:361-70; PMID:12374095; https://doi.org/10.2174/1389203013380991
   PubMed Web of Science ®Google Scholar
• Amie SM, Bambara RA, Kim B. GTP is the primary activator of the anti-HIV restriction factor SAMHD1. J Biol Chem 2013; 288:25001-6; PMID:23880768; https://doi.org/10.1074/jbc.C113.493619
   PubMed Web of Science ®Google Scholar
• Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Strom CE, Svensson LM, Schultz N, Lundback T, Einarsdottir BO, et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature 2014; 508:215-21; PMID:24695224; https://doi.org/10.1038/nature13181
   PubMed Web of Science ®Google Scholar
• Rudd SG, Valerie NC, Helleday T. Pathways controlling dNTP pools to maintain genome stability. DNA Repair (Amst) 2016; 44:193-204; PMID:27311542; https://doi.org/10.1016/j.dnarep.2016.05.032
   PubMed Web of Science ®Google Scholar
• Huber AD, Michailidis E, Schultz ML, Ong YT, Bloch N, Puray-Chavez MN, Leslie MD, Ji J, Lucas AD, Kirby KA, et al. SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2014; 58:4915-9; PMID:24867973; https://doi.org/10.1128/AAC.02745-14
   PubMed Web of Science ®Google Scholar
• Honma Y, Niitsu N. Vidarabine and 2-deoxycoformycin as antileukemic agents against monocytic leukemia. Leuk Lymphoma 2000; 39:57-66; PMID:10975384; https://doi.org/10.3109/10428190009053539
   PubMed Web of Science ®Google Scholar
• Sueda T, Sakai D, Kudo T, Sugiura T, Takahashi H, Haraguchi N, Nishimura J, Hata T, Hayashi T, Mizushima T, et al. Efficacy and safety of regorafenib or TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies. Anticancer Res 2016; 36:4299-306; PMID:27466548
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Nishio M, Satouchi M, Valmadre G, Niho S, Galetta D, Cortinovis D, Benedetti F, Yoshihara E, Makris L, et al. A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy. Lung Cancer 2016; 100:20-3; PMID:27597276; https://doi.org/10.1016/j.lungcan.2016.06.023
   PubMed Web of Science ®Google Scholar
• Bando H, Doi T, Muro K, Yasui H, Nishina T, Yamaguchi K, Takahashi S, Nomura S, Kuno H, Shitara K, et al. A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201). Eur J Cancer 2016; 62:46-53; PMID:27208903; https://doi.org/10.1016/j.ejca.2016.04.009
   PubMed Web of Science ®Google Scholar
• Griffith JF, Fitzwilliam JF, Casagrande S, Butler SR. Experimental herpes simplex virus encephalitis: Comparative effects of treatment with cytosine arabinoside and adenine arabinoside. J Infect Dis 1975; 132:506-10; PMID:171318; https://doi.org/10.1093/infdis/132.5.506
   PubMed Web of Science ®Google Scholar
• Miyamoto Y, Lenz HJ, Baba H. A novel antimetabolite: TAS-102 for metastatic colorectal cancer. Expert Rev Clin Pharmacol 2016; 9:355-65; PMID:26677869; https://doi.org/10.1586/17512433.2016.1133285
   PubMed Web of Science ®Google Scholar
• Elamin YY, Rafee S, Osman N, KJ OB, Gately K. Thymidine phosphorylase in cancer; Enemy or friend? Cancer Microenviron 2016; 9:33-43; PMID:26298314; https://doi.org/10.1007/s12307-015-0173-y
   PubMed Web of Science ®Google Scholar
• Lenz HJ, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treat Rev 2015; 41:777-83; PMID:26428513; https://doi.org/10.1016/j.ctrv.2015.06.001
   PubMed Web of Science ®Google Scholar
• Momparler RL, Rossi M, Bouchard J, Vaccaro C, Momparler LF, Bartolucci S. Kinetic interaction of 5-AZA-2′-deoxycytidine-5′-monophosphate and its 5′-triphosphate with deoxycytidylate deaminase. Mol Pharmacol 1984; 25:436-40; PMID:6203026
   PubMed Web of Science ®Google Scholar
• Serdjebi C, Milano G, Ciccolini J. Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs. Expert Opin Drug Metab Toxicol 2015; 11:665-72; PMID:25495470; https://doi.org/10.1517/17425255.2015.985648
   PubMed Web of Science ®Google Scholar
• Heinemann V, Plunkett W. Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3,4,5,6-tetrahydrodeoxyuridine. Biochem Pharmacol 1989; 38:4115-21; PMID:2688654; https://doi.org/10.1016/0006-2952(89)90693-X
   PubMed Web of Science ®Google Scholar
• Jansen RS, Rosing H, Schellens JH, Beijnen JH. Deoxyuridine analog nucleotides in deoxycytidine analog treatment: Secondary active metabolites? Fundam Clin Pharmacol 2011; 25:172-85; PMID:20199587; https://doi.org/10.1111/j.1472-8206.2010.00823.x
   PubMed Web of Science ®Google Scholar
• Riva C, Barra Y, Carcassonne Y, Cano JP, Rustum Y. Effect of tetrahydrouridine on metabolism and transport of 1-beta-D-arabinofuranosylcytosine in human cells. Chemotherapy 1992; 38:358-66; PMID:1286578; https://doi.org/10.1159/000239026
   PubMed Web of Science ®Google Scholar
• Ferraris D, Duvall B, Delahanty G, Mistry B, Alt J, Rojas C, Rowbottom C, Sanders K, Schuck E, Huang KC, et al. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase. J Med Chem 2014; 57:2582-8; PMID:24520856; https://doi.org/10.1021/jm401856k
   PubMed Web of Science ®Google Scholar
• McIntosh EM, Haynes RH. dUTP pyrophosphatase as a potential target for chemotherapeutic drug development. Acta Biochim Pol 1997; 44:159-71; PMID:9360704
   PubMed Web of Science ®Google Scholar
• Grasser FA, Romeike BF, Niedobitek G, Nicholls J, Kremmer E. dUTPase in human neoplastic cells as a potential target for therapeutic intervention. Curr Protein Pept Sci 2001; 2:349-60; PMID:12369931; https://doi.org/10.2174/1389203013381053
   PubMed Web of Science ®Google Scholar
• Miyakoshi H, Miyahara S, Yokogawa T, Endoh K, Muto T, Yano W, Wakasa T, Ueno H, Chong KT, Taguchi J, et al. 1,2,3-Triazole-containing uracil derivatives with excellent pharmacokinetics as a novel class of potent human deoxyuridine triphosphatase inhibitors. J Med Chem 2012; 55:6427-37; PMID:22715973; https://doi.org/10.1021/jm3004174
   PubMed Web of Science ®Google Scholar
• Saito K, Nagashima H, Noguchi K, Yoshisue K, Yokogawa T, Matsushima E, Tahara T, Takagi S. First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers. Cancer Chemother Pharmacol 2014; 73:577-83; PMID:24452393; https://doi.org/10.1007/s00280-014-2383-2
   PubMed Web of Science ®Google Scholar
• Valerie NC, Hagenkort A, Page BD, Masuyer G, Rehling D, Carter M, Bevc L, Herr P, Homan E, Sheppard NG, et al. NUDT15 Hydrolyzes 6-Thio-DeoxyGTP to Mediate the Anticancer Efficacy of 6-Thioguanine. Cancer Res 2016; 76:5501-11; PMID:27530327; https://doi.org/10.1158/0008-5472.CAN-16-0584
   PubMed Web of Science ®Google Scholar
• Moriyama T, Nishii R, Perez-Andreu V, Yang W, Klussmann FA, Zhao X, Lin TN, Hoshitsuki K, Nersting J, Kihira K, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet 2016; 48:367-73; PMID:26878724; https://doi.org/10.1038/ng.3508
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Nersting J, Nielsen SN, Heyman M, Wesenberg F, Kristinsson J, Vettenranta K, Schroeder H, Weinshilboum R, Jensen KL, et al. Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts? Pediatr Blood Cancer 2016; 63:2104-11; PMID:27447547; https://doi.org/10.1002/pbc.26139
   PubMed Web of Science ®Google Scholar
• Goncalves A, Karayel E, Rice GI, Bennett KL, Crow YJ, Superti-Furga G, Burckstummer T. SAMHD1 is a nucleic-acid binding protein that is mislocalized due to aicardi-goutieres syndrome-associated mutations. Hum Mutat 2012; 33:1116-22; PMID:22461318; https://doi.org/10.1002/humu.22087
   PubMed Web of Science ®Google Scholar
• Menendez-Arias L, Betancor G, Matamoros T. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors. Antiviral Res 2011; 92:139-49; PMID:21896288; https://doi.org/10.1016/j.antiviral.2011.08.020
   PubMed Web of Science ®Google Scholar
• Emura T, Murakami Y, Nakagawa F, Fukushima M, Kitazato K. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 2004; 13:545-9; PMID:15010854
   PubMed Web of Science ®Google Scholar
• Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, Krushel L, Aukerman SL, Heise C, MacBeth KJ. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010; 5:e9001; PMID:20126405; https://doi.org/10.1371/journal.pone.0009001
   PubMed Web of Science ®Google Scholar
• Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483:603-7; PMID:22460905; https://doi.org/10.1038/nature11003
   PubMed Web of Science ®Google Scholar
• Seashore-Ludlow B, Rees MG, Cheah JH, Cokol M, Price EV, Coletti ME, Jones V, Bodycombe NE, Soule CK, Gould J, et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov 2015; 5:1210-23; PMID:26482930; https://doi.org/10.1158/2159-8290.CD-15-0235
   PubMed Web of Science ®Google Scholar
• Rees MG, Seashore-Ludlow B, Cheah JH, Adams DJ, Price EV, Gill S, Javaid S, Coletti ME, Jones VL, Bodycombe NE, et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol 2016; 12:109-16; PMID:26656090; https://doi.org/10.1038/nchembio.1986
   PubMed Web of Science ®Google Scholar